National Pension Service Buys 1,640,940 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

National Pension Service increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 107.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,170,640 shares of the company's stock after acquiring an additional 1,640,940 shares during the period. National Pension Service owned about 0.28% of Teva Pharmaceutical Industries worth $57,135,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company's stock valued at $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. Maple Rock Capital Partners Inc. lifted its stake in Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company's stock valued at $61,568,000 after acquiring an additional 1,770,000 shares in the last quarter. Truist Financial Corp boosted its holdings in Teva Pharmaceutical Industries by 7.0% during the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company's stock worth $63,135,000 after acquiring an additional 254,483 shares during the last quarter. Iron Triangle Partners LP grew its stake in shares of Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company's stock worth $39,083,000 after acquiring an additional 1,469,864 shares in the last quarter. Finally, Tri Locum Partners LP raised its holdings in shares of Teva Pharmaceutical Industries by 15.1% in the second quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company's stock valued at $41,442,000 after purchasing an additional 334,119 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

TEVA traded down $1.34 during trading on Wednesday, reaching $17.43. The stock had a trading volume of 18,205,241 shares, compared to its average volume of 9,296,835. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market cap of $19.75 billion, a PE ratio of -44.69, a PEG ratio of 1.34 and a beta of 0.87. The business has a 50-day moving average of $18.00 and a 200-day moving average of $17.06. Teva Pharmaceutical Industries Limited has a one year low of $8.55 and a one year high of $19.31.

Analyst Ratings Changes

TEVA has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th. Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and a consensus price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.